Breaking News

Data Presented from First U.S. Clinical Trial of Photodynamic Bone Stabilization System

By IlluminOss Medical | November 3, 2016

Findings support the benefits of applying minimally invasive system to the treatment of pathological fractures.

IlluminOss Medical, a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair, has announced that Richard Terek, M.D., presented the first preliminary data from its U.S. pivotal clinical trial at the recent Musculoskeletal Tumor Society (MSTS) Meeting in Detroit. The IlluminOss System is the world’s only system of its kind that supports the treatment of fractures using patient-specific bone conforming intramedullary implants.
IlluminOss’ LightFix Trial is a multi-center study of the IlluminOss System for the treatment of impending and actual pathological fractures in the humerus from metastatic bone disease Preliminary results from the U.S. trial measured pain and functional improvement, as well as evaluated safety and performance.
“The investigators found that the technical nature and attributes of the product were viewed to be easier and faster to use, with no limitations to the use of adjunctive hardware,” said Dr. Richard Terek.
Dr. Terek, an orthopedic surgeon and musculoskeletal oncologist who specializes in reconstructive surgery and musculoskeletal oncology and serves as professor in the department of orthopedic surgery at The Warren Alpert Medical School of Brown University, used the IlluminOss System in the treatment of patients at Rhode Island Hospital and is the first to publicly present trial results.
“The preliminary results of the LightFix trial have been extremely positive in that the investigators found that the device was less invasive than many standard orthopedic implants. The early data suggests that the patients achieved a decrease in pain and an increase in return to function through the use of the IlluminOss implant,” said Dr. Terek. “We are encouraged with the results of the IlluminOss System and look forward to its availability in the USA. It will offer the U.S. market a new and much-needed alternative for the treatment of patients with metastatic bone disease and other complex fractures.”
The IlluminOss System was developed with the potential to provide better patient experiences and outcomes than currently used nails and plates. IlluminOss has been used since 2010 in the treatment of patients in international markets, where it has been observed to result in smaller incisions, shorter procedure times, and more rapid post-procedure patient mobility with reduced hospital stays and lower complication rates for patients. 
“This first presentation of our clinical data is consistent with the positive results we have seen in Europe and is further substantiation of the merits of our platform’s capabilities and how they may benefit the orthopedic community,” said Manny Avila, CEO, IlluminOss. “We look forward to the presentation of the completed LightFix trial results and the opportunity to provide the product to a much broader patient base.”

Related News:

Related Markets:

  • Filling the Gap In Spinal Fusion

    Filling the Gap In Spinal Fusion

    Sean Fenske, Editor||January 31, 2017
    One company has addressed the “performance gap” that’s left in spinal fusion procedures with a unique technology solution.

  • The Biologic Shift

    The Biologic Shift

    Sean Fenske, Editor||January 17, 2017
    As doctors and surgeons evaluate biologic options, emerging OEMs are focusing exclusively on this type of offering.

  • Specialized Imaging

    Specialized Imaging

    Sean Fenske, Editor||January 12, 2017
    Esaote’s G-Scan Brio is a versatile MRI system ideally suited to imaging disc herniation at multiple positions.

  • Status Quo

    Status Quo

    Michael Barbella, Managing Editor||November 22, 2016
    The orthopedic industry’s unexceptional year lacked the poignant moments and historic flavor of 2015.

  • New FDA Guidance for 510(k) Submission of Orthopedic Medical Implants

    New FDA Guidance for 510(k) Submission of Orthopedic Medical Implants

    Martell Winters, Senior Scientist and Consulting Manager; Quinton Inglet, Section Leader, Bacterial Endotoxin Testing, Nelson Laboratories||November 22, 2016
    The document could have a significant impact on the testing regimen for implant device manufacturers.

  • Precision, Speed,  and Cost—Oh My!

    Precision, Speed, and Cost—Oh My!

    Sam Brusco, Associate Editor||November 22, 2016
    Orthopedic device prototyping labs work to collude precision with short lead times and monetary concerns.